Health Dictionary Find a Doctor

Allergic conjunctivitis secondary prevention

Overview

Overview

Early diagnosis and treatment constitute the secondary prevention of allergic conjunctivitis. It involves both pharmacological and non-pharmacological measures.

Secondary Prevention

Secondary Prevention

Early diagnosis

The diagnosis should be confirmed and the severity assessed by a proper history and a thorough physical examination.

The dual-activity agents are considered first-line. When symptoms and signs remain uncontrolled, a short course of topical ophthalmic steroids may be considered which might need monitoring by an eye care specialist is necessary if prescribed for longer term. Other treatments include concomitant use of nasal steroids, oral anti-histamines and/or topical ophthalmic NSAIDs. Immunotherapy, either subcutaneous or sublingual, can be considered when medical therapy is insufficient, poorly tolerated or for patient preference.

References

References

  1. Dupuis P, Prokopich CL, Hynes A, Kim H (2020). “A contemporary look at allergic conjunctivitis”. Allergy Asthma Clin Immunol. 16: 5. doi:10.1186/s13223-020-0403-9. PMC 6975089 Check |pmc= value (help). PMID 31993069.
  2. 2.0 2.1 Sánchez-Hernández MC, Montero J, Rondon C, Benitez del Castillo JM, Velázquez E, Herreras JM; et al. (2015). “Consensus document on allergic conjunctivitis (DECA)”. J Investig Allergol Clin Immunol. 25 (2): 94–106. PMID 25997302.
  3. Bielory L, Meltzer EO, Nichols KK, Melton R, Thomas RK, Bartlett JD (2013). “An algorithm for the management of allergic conjunctivitis”. Allergy Asthma Proc. 34 (5): 408–20. doi:10.2500/aap.2013.34.3695. PMID 23998237.

Template:WH Template:WS

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH